Cullinan Oncology LLC
Statements
Cash Flow
Cullinan Oncology LLC (CGEM) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -38 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 14 | Q4 14 | Q1 15 | Q2 15 | Q3 15 | Q4 15 | Q1 16 | Q2 16 | Q3 16 | Q4 16 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | 0.0 | 0.0 | -0.2 | 0.0 | 0.0 | 0.0 | -5.1 | -5.1 | -5.9 | -4.9 | -5.0 | -6.3 | -9.1 | -9.4 | -1.5 | -16 | -11 | -15 | -22 | -25 | -54 | -25 | -51 | -31 | -34 | -18 | -38 | -36 | -34 | -37 | -43 | -58 | -37 | -38 | -46 | -38 | -159 | |
| – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | |
| – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | 15 | 3.5 | 4.2 | 4.6 | 12 | 6.6 | 8.6 | 5.3 | 7.5 | 7.3 | 7.9 | 7.7 | 7.5 | 8.2 | 11 | 9.4 | 9.6 | 9.4 | 9.9 | 9.5 | 7.3 | 7.6 | 8.4 | 33 | |
| – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | -0.3 | – | -0.2 | 0.6 | -0.5 | 14 | 5.2 | 4.2 | 4.6 | 12 | -13 | -202 | 5.4 | 7.4 | 7.3 | 7.9 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -0.4 | -0.4 | 0.3 | -0.2 | 0.1 | 0.9 | 1.3 | 4.5 | -6.7 | -4.8 | 2.2 | 5.8 | 3.0 | 48 | -35 | -5.0 | 1.2 | -4.6 | -0.2 | 3.3 | -5.9 | -1.1 | 1.8 | 4.8 | -1.8 | 4.2 | 5.5 | 6.1 | -3.3 | 4.6 | 13 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.3 | 0.3 | 0.3 | 0.9 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 37 | 0.0 | 0.0 | 0.0 | 37 | |
| – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | -35 | -27 | 12 | -1.9 | 11 | -138 | -155 | -26 | -16 | 35 | 301 | -58 | -29 | 15 | 12 | -43 | 51 | 13 | -185 | 20 | 16 | 37 | 53 | 67 | 22 | 32 | 41 | 163 | |
| – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | -0.3 | – | – | – | 0.0 | 267 | 0.9 | 0.6 | 2.7 | 2.7 | 2.8 | 1.4 | -31 | 1.8 | 38 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | 0.0 | 0.0 | 0.2 | -1.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | 0.8 | 0.8 | 0.8 | 0.8 | -0.8 | 0.2 | -2.2 | – | – | – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | |
| 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.9 | 0.9 | 0.0 | 84 | 14 | 7.0 | 1.2 | 125 | 265 | 0.9 | 0.6 | 2.7 | 3.5 | 2.0 | 1.4 | -33 | 1.8 | 39 | 0.1 | 0.2 | 1.1 | 262 | 1.3 | 1.6 | 0.0 | 0.4 | 0.0 | 0.7 | 0.4 | 1.1 | 2.2 | |
| – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4.2 | -4.2 | -5.9 | 63 | -18 | 5.7 | 41 | 127 | 125 | -170 | -36 | -28 | 16 | 277 | -111 | -87 | -34 | 20 | -77 | 34 | -24 | 41 | -13 | -19 | -6.4 | -3.8 | 31 | -15 | -13 | 3.6 | 5.8 | |
| – | – | – | – | – | – | – | – | – | – | -5.1 | -5.1 | -5.9 | -4.9 | -5.0 | -6.3 | -9.1 | -9.4 | -1.5 | -16 | -11 | -15 | -22 | -25 | -55 | -26 | -51 | -31 | -34 | -18 | -38 | -36 | -34 | -37 | -43 | -58 | -37 | -38 | -46 | -38 | -159 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.